Five things for pharma marketers to know: Tuesday, June 20, 2017

Share this content:

1. Novartis announced positive Phase-III results for brolucizumab, a potential competitor to Regeneron's eye-disorder drug Eylea. Leerink analyst Seamus Fernandez said, “We expect [brolucizumab] to be a major competitor in the U.S. to Eylea and Lucentis.” (Endpts)

2. AstraZeneca EVP of oncology Jamie Freedman said the drugmaker faces a “critical transition point” in its upcoming readout of the MYSTIC trial, which is studying the effect of immunotherapies durvalumab and tremelimumab in patients with non-small cell lung cancer. (WSJ)

3. The Association of American Medical Colleges predicted that demand for physicians will continue to outgrow supply. The group estimates that, by 2025, the shortage will be between 34,600 and 88,000 physicians. (Modern Healthcare)

4. Two researchers from Harvard Medical School argued in an op-ed that the CREATES Act, a bill introduced in April designed to make it easier for generic drugs to come to market, could help combat rising drug prices. (Bloomberg)

5. After a long contract dispute with previous employer AstraZeneca, GlaxoSmithKline's new president of global pharmaceuticals, Luke Miels, has a start date of September 4. Miels previously headed up AstraZeneca's European business. (Reuters)

Share this content:
Scroll down to see the next article